E-LIB Suche - Ergebnisse für: Kiesewetter B

1

Methodological and reporting standards for quality-of-life ..:

Oosting, S.F. ; Barriuso, J. ; Bottomley, A....
Annals of Oncology. 34 (2023) 4 - p. 431-439 , 2023

Link: https://doi.org/10.1016/..

2

CLinicopathological characteristics of extranodal marginal ..:

Steinbrecher, O. ; Kiesewetter, B. ; Dolak, W...
Hematological Oncology. 41 (2023) S2 - p. 394-394 , 2023

Link: https://doi.org/10.1002/..

3

Assessment of Helicobacter pylori (HP) negative gastric MAL..:

Raderer, M. ; Simonitsch‐Klupp, I. ; Staudacher, M....
Hematological Oncology. 41 (2023) S2 - p. 294-294 , 2023

Link: https://doi.org/10.1002/..

4

Managing hematological cancer patients during the COVID-19 ..:

Buske, C. ; Dreyling, M. ; Alvarez-Larrán, A....
ESMO Open. 7 (2022) 2 - p. 100403 , 2022

Link: https://doi.org/10.1016/..

5

OS03.7.A Clinical characteristics, treatment and long-term ..:

Wolff, L ; Steindl, A ; Dieckmann, K...
Neuro-Oncology. 24 (2022) Supplement_2 - p. ii13-ii13 , 2022

Link: https://doi.org/10.1093/..

6

Corrigendum to 'How I treat medullary thyroid cancer':

Kiesewetter, B. ; Riss, P. ; Scheuba, C..
ESMO Open. 7 (2022) 3 - p. 100516 , 2022

Link: https://doi.org/10.1016/..

7

Pulmonary neuroendocrine tumours and somatostatin receptor ..:

Kiesewetter, B. ; Mazal, P. ; Kretschmer-Chott, E...
ESMO Open. 7 (2022) 3 - p. 100478 , 2022

Link: https://doi.org/10.1016/..

8

How I treat medullary thyroid cancer:

Kiesewetter, B. ; Riss, P. ; Scheuba, C..
ESMO Open. 6 (2021) 3 - p. 100183 , 2021

Link: https://doi.org/10.1016/..

9

Biases in study design, implementation, and data analysis t..:

Gyawali, B. ; de Vries, E.G.E. ; Dafni, U....
ESMO Open. 6 (2021) 3 - p. 100117 , 2021

Link: https://doi.org/10.1016/..

10

DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS A..:

Raderer, M. ; Dolak, W. ; Simonitsch‐Klupp, I..
Hematological Oncology. 37 (2019) S2 - p. 263-263 , 2019

Link: https://doi.org/10.1002/..

11

EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVI..:

Conconi, A. ; Thieblemont, C. ; Cascione, L....
Hematological Oncology. 37 (2019) S2 - p. 179-180 , 2019

Link: https://doi.org/10.1002/..

12

TRANSFORMED MUCOSA‐ASSOCIATED LYMPHOID TISSUE LYMPHOMAS: A ..:

Kiesewetter, B. ; Lamm, W. ; Dolak, W....
Hematological Oncology. 37 (2019) S2 - p. 264-264 , 2019

Link: https://doi.org/10.1002/..

13

FIRST LINE SYSTEMIC TREATMENT IN MUCOSA‐ASSOCIATED LYMPHOID..:

Kiesewetter, B. ; Lamm, W. ; Mayerhoefer, M.E....
Hematological Oncology. 37 (2019) S2 - p. 449-450 , 2019

Link: https://doi.org/10.1002/..

14

CLARITHROMYCIN AS a "REPURPOSING DRUG" AGAINST LYMPHOMAS: S..:

Ferreri, A.J. ; Cecchetti, C. ; Kiesewetter, B....
Hematological Oncology. 35 (2017) S2 - p. 86-87 , 2017

Link: https://doi.org/10.1002/..

15

PROGRESSION‐FREE SURVIVAL FOLLOWING LENALIDOMIDE‐BASED TREA..:

Kiesewetter, B. ; Mayerhoefer, M.E. ; Dolak, W....
Hematological Oncology. 35 (2017) S2 - p. 212-213 , 2017

Link: https://doi.org/10.1002/..